{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-088054","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.154454+00:00","generated_at":"2026-05-31T09:57:14.684160+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Marker Therapeutics awarded $2M NIH SBIR grant for MT-601 Phase 1 in CAR-relapsed NHL","bullets":["Awarded $2 million non-dilutive grant from NIH SBIR to support Phase 1 APOLLO study of MT-601 in NHL patients relapsed after anti-CD19 CAR T therapy.","Grant based on preliminary clinical data (Sept 2023) and non-clinical data (May 2023) showing anti-tumor activity of MT-601.","Company has now received over $19 million in total non-dilutive funding proceeds.","APOLLO study evaluates multiTAA-specific T cell product; initial patients showed objective responses with no CRS or ICANS."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-088054","json":"https://secwatch.observer/filing/0001104659-24-088054.json","markdown":"https://secwatch.observer/filing/0001104659-24-088054.md","text":"https://secwatch.observer/filing/0001104659-24-088054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924088054/0001104659-24-088054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924088054/tm2421372d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:57:14.684160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}